vimarsana.com

Latest Breaking News On - Samantha floam - Page 1 : vimarsana.com

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced five presentations, including two featured oral plenary presentations, on.

United statesNew yorkNordrhein westfalenHans van dongenMark jacobsonDarren oplandMichael thorpySamantha floamJohannes gutenbergDepartment of neurologyMontefiore medical centerProfessor at washington state universityAmerican academy of sleep medicineAxsome therapeutics incCorporate communicationsDrug administration

Axsome to Present Findings on Solriamfetol s Cognitive Benefits

Axsome will unveil data demonstrating solriamfetol's ability to enhance cognitive functioning in patients with OSA and narcolepsy.

Nordrhein westfalenJohannes gutenbergMichael thorpySolriamfetol sunosiUlf kallweitHans van dongenSamantha floamWashington state universityMontefiore medical centerWake disorders centerDepartment of neurologyAxsome therapeutics incMedicine centerUniversity witten herdeckeAxsome therapeuticsTherapeutics inc

Sunosi Improving Cognitive Function in OSA Patients with EDS

Sunosi (solriamfetol) is demonstrating improvement in cognitive function in patients with excessive daytime sleepiness associated with OSA.

United statesEileen learySamantha floamDrug administrationAmerican society of clinical psychopharmacologyAxsome therapeutic incAmerican societyClinical psychopharmacologyAnnual meetingCognitive functionCognitive impairment associatedExcessive daytime sleepinessObstructive sleep apneaDaytime sleepinessReal world studyPotential mechanisms

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with. | May 30, 2023

United statesNew yorkGregory mattinglyRakesh jainEileen learyAndrew cutlerSamantha floamDarren oplandZachariah thomasMark jacobsonClinical professor of psychiatry at washington universityAxsome therapeutics incMd texas tech university school of medicineWorld trade centerNational survey on drugSk biopharmaceuticals co ltd

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

NEW YORK, April 21, 2023 Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today. | April 21, 2023

United statesUnited kingdomNew yorkMark jacobsonStuartj tepperAxsome moDarren oplandEileen learyZachariah thomasSamantha floamHans van dongenSk biopharmaceuticals co ltdAffairs at axsomeClinical development at axsomeAxsome therapeutics incGeisel school of medicine at dartmouth

vimarsana © 2020. All Rights Reserved.